NEW RESEARCH—In a retrospective cohort study, frailty—an approximation of biological age—was a risk factor for severe infection in older adults with ANCA-associated #vasculitis thelancet.com/journals/lanrh… @SattuiSEMD Zach Wallace

✅ Current pipeline of investigational agents / drug development in #Lupus, updated with #ACR2024 data ⬇️ What would you add? Which ones are the most promising? There is truly hope for patients with #SLE. Please do let me know if I have forgotten something & I will reupdate.

Interesting! Study of pts w/ ANA(-) & dsDNA(+). 1 in 5 dx with APLS! Have others seen that? I have been disgregarding this pattern, though some of that is related to my in-house assay (seems overly-sensitive) & my bias against overdiagnosis #ACR24 Dr. John Cush Abstr#2391

Provocative study suggests SLE has changed. Big picture: less physical manifestations, more serologic Andrea Fava why isn't this just more-testing & more-sensitive testing shifting the phenotype of who we diagnose? #ACR24 Dr. John Cush Abstr#2413

Lots of data on TYKs including much supporting efficacy in interferon inhibition Can we really call interferon signalling a "central" pathway in SLE? Inhibiting it has been modestly successful, at best, and mostly for skin dx #ACR24 Dr. John Cush Abstr#2434

Important study in SLE: out of 590 pts with pericarditis, 20% had recurrence w/in 1 year Higher in early dx, younger pts, higher dx activity, & pred exposure Is prednisone risk confounding by indication? Or causative? #ACR24 Dr. John Cush Andrea Fava Abstr#2372

Depressing finding re:glucocorticoid discontinuation in SLE No improvement over decades in rate of GC discontinuation; if anything, we start more GC than ever Alí Duarte, MD help me out here; why haven't we made more progress? #ACR24 Dr. John Cush Abstr#2421

Selective TYK2i zasocitinib, results of Phase 2 DBRCT Dose dependent improvements in various PsA outcomes; NNT~5 for DAS28 remission, NNT~20 for PASDAS Hard to compare to current agents, somewhere between JAKs (woot!) & "apremlist zone" 🫣 #ACR24 Dr. John Cush Abstr#2584 #ACRbest

🆕 #ACR24 | Updated Guidelines for Lupus Nephritis Treatment & Management 🫘 Highlights 🔶 • Critical role of renal biopsy • Differences for treatment by LN Class • Adjunctive Rx w/ HCQ & RAASi • GC pulse ⇢ *moderate/low* dose PDN #Lupus #NephTwitter #RheumTwitter

#ACR24 Thanks to The Lancet Rheumatology for the warm reception. It was great to see everyone Dr. Fabian Proft André Ribeiro Jeffrey Sparks MD MMSc @SattuiSEMD Mike Putman #ElizabethVolkmann

PHOENYCS GO, RCT of dapirplizumab, novel CD40Li in SLE Met primary endpoint (NNT~6 for BICLA) & numerical improvements in many other endpts 1 MI & 1 death from infection over 213 pts Encouraging for sure! Second phase 3 being launched #ACR24 Dr. John Cush Abstr#L16 #ACRbest

Allogenic CD19 CAR-NK cells in SLE, experience w/22 pts 68% LLDAS remission, no relapse As with others, B cell reconstitution w/naive B cells & surprising safety (only 2 cases low-grade CRS) Lots of potential; still figuring out the particulars #ACR24 Dr. John Cush Abstr#L17

All-caps abstract text throw-down by Michelle Petri re:fractures in SLE 😆 I keep saying this; our obsesssion with vitamin d is not commensurate w/reality It's. The. Prednisone. #ACR24 Dr. John Cush Abstr#2679 #ACRBest

Really looking forward to participating this year - check it out and come join us!

Just submitted mine!!! Last minute y’all get ‘em in!